Investing

Celldex Therapeutics : CLDX

CLDX

Stock Data

$25.92

$0.93 (3.46%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Celldex Therapeutics Inc is a pioneering biopharmaceutical firm focused on crafting innovative antibody-based treatments for inflammatory, allergic, autoimmune, and other severe diseases. With a notable drug candidate, CDX-0159, currently in Phase II trials targeting the KIT receptor tyrosine kinase, Celldex is at the forefront of addressing unmet medical needs. Founded in 1983 and based in Hampton, New Jersey, the company also benefits from strategic research partnerships, including one with Yale University, to advance its mission of developing life-changing therapeutics.

All Celldex Therapeutics Articles

48 Articles

Chris Lange | Aug 30, 2021 at 8:49 AM EDT

Monday’s Top Analyst Upgrades and Downgrades: American Express, Capital One, Levi Strauss, Pinterest, Peloton, Synchrony, T-Mobile and More

Monday’s top analyst upgrades and downgrades included American Express, Capital One, Levi Strauss, Pinterest, Peloton, Synchrony and T-Mobile.

Chris Lange | Feb 8, 2019 at 8:40 AM EST

Major 2019 Biopharma Catalysts Coming in February and March

Here, 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and U.S. Food…

Paul Ausick | Jun 22, 2018 at 4:04 PM EDT

Ambev, Renren Slide into Friday’s 52-Week Low Club

Ambev, Renren, Celldex, and Yatra Online all posted new 52-week lows Friday.

Paul Ausick | Jun 21, 2018 at 4:04 PM EDT

General Electric, Starbucks Drop into Thursday’s 52-Week Low Club

General Electric, Starbucks, General Dynamics, and Celldex all posted new 52-week lows Thursday.

Paul Ausick | Jun 20, 2018 at 4:07 PM EDT

Oracle, Starbucks Plunge into Wednesday’s 52-Week Low Club

Oracle, Starbucks, Helios and Matheson, and Celldex all posted new 52-week lows Wednesday.

Paul Ausick | May 30, 2018 at 4:04 PM EDT

Gogo, Tesaro Drop into Wednesday’s 52-Week Low Club

Banco Bradesco, Gogo, Tesaro, and Celldex all posted new 52-week lows Wednesday.

Paul Ausick | May 22, 2018 at 4:04 PM EDT

JC Penney, Spectra Energy Slip into Tuesday’s 52-Week Low Club

J.C. Penney, Helios and Matheson, Celldex, and Spectra Energy Partners all posted new 52-week lows Tuesday.

Paul Ausick | Apr 18, 2018 at 4:04 PM EDT

MGIC, Juniper Networks Slide into Wednesday’s 52-Week Low Club

MGIC Investment Group, Celldex Therapeutics, Juniper Networks, and Healthcare Services Group all posted new 52-week lows on Wednesday.

Paul Ausick | Apr 16, 2018 at 4:04 PM EDT

Celldex, Acacia Plummet into Monday’s 52-Week Low Club

Celldex Therapeutics, Acacia Communications, Apricus Biosciences, and Ctrp.com all posted new 52-week lows Monday.

Chris Lange | Apr 16, 2018 at 8:40 AM EDT

Why Celldex Therapeutics Is Getting Crushed

Celldex Therapeutics shares were absolutely crushed on Monday morning after the firm announced results to its midstage breast cancer study.

Chris Lange | Dec 30, 2017 at 8:55 AM EST

30 Big Biotech Events Coming in 2018

Jefferies has compiled a list of over 30 biotech events taking place in 2018 that could result in significant stock…

Jon C. Ogg | Aug 1, 2017 at 9:05 AM EDT

Top Analyst Upgrades and Downgrades: American Airlines, Boeing, Cabot Oil & Gas, Pandora, Southern Co., Vertex and Many More

The top analyst upgrades, downgrades and other research calls include American Airlines, Boeing, Cabot Oil & Gas, Pandora Media, Southern…

Paul Ausick | Jun 6, 2017 at 4:04 PM EDT

Macy’s, Tegna Drop into Tuesday’s 52-Week Low Club

Macy's, Tegna, Celldex, and DryShips posted new 52-week lows Tuesday.

Chris Lange | Jun 6, 2017 at 1:25 PM EDT

Celldex Therapeutics Sinks Following ASCO Results

Celldex Therapeutics was another big mover coming out of the Annual Meeting for the American Society of Clinical Oncology (ASCO).…

Chris Lange | Oct 4, 2016 at 9:15 AM EDT

Key FDA Decisions and Trial Results Expected in October

24/7 Wall St. has collected several big FDA decisions and mid-stage to late-stage trials that should be announced in October.